Clinical trial
A Phase III Study of the Conversion Efficacy and Safety of Repeated Intravenous Doses of RSD1235 in Subjects With Atrial Fibrillation or Atrial Flutter Following Valvular and/or Coronary Artery Bypass Graft Surgery
NCT00125320 is registered in ClinicalTrials.gov with Astellas Pharma Inc as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase III Study of the Conversion Efficacy and Safety of Repeated Intravenous Doses of RSD1235 in Subjects With Atrial Fibrillation or Atrial Flutter Following Valvular and/or Coronary Artery Bypass Graft Surgery
- Lead sponsor
- Astellas Pharma Inc
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- June 30, 2004
- Completion date
- February 28, 2007
- Enrollment
- 190 (actual)
- Sites
- 22
Conditions
As the registry lists them; a condition with its own page is linked.